Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This is a promotional website developed by AstraZeneca and intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
OlympiA: Efficacy and safety data in gBRCAm, HER2- negative eBC
Practicalities of incorporating PARP
inhibitors into current practice
The OlympiAD Regimen: Targeting gBRCA in advanced Breast Cancer (aBC)
The Expert on Demand programme offers a novel opportunity for healthcare professionals to attend interactive virtual presentations and Q&A sessions with an experienced practitioner on a given topic.
The “on demand” nature offers a personalised approach to education on various promotional subject matters related to Lynparza early breast cancer treatment. There is no requirement to travel as the meeting takes place via a virtual platform.
Please see a list of available topics below.
Should you wish to engage in the Expert on Demand programme, please submit an enquiry below.
Module Summary: The aim of this module is to demonstrate that gBRCAm patients are a distinct group of patients requiring an individualised care plan due to differences in underlying tumour biology vs. non-gBRCAm patients.
Module Summary: In this module, an overview of the OlympiA trial and relevant data will be provided.
Module Summary: The aim of this module is to discuss the considerations for the management of patients treated with Olaparib in clinical practice, including dosage and AE management.
Early breast cancer patient booklet
A patient guide to treatment for early breast cancer
Advanced breast cancer patient booklet
A patient guide to treatment for advanced breast cancer
Genetic testing booklet
A patient guide to help understand genetic testing in breast cancer
The OlympiA trial for high-risk, HER2-, gBRCAm eBC
A summary of the OlympiA trial and key data points including the latest 6-year follow-up
The OlympiAD trial for HER2-, gBRCAm aBC
A summary of the OlympiAD trial and key data points
BRCA Testing pathway decision tree
A simplified guide on how to identify eligibility for BRCA testing and test your breast cancer patients
gBRCA testing pathway for patients with breast cancer symptoms
Review this pathway that was produced and funded by AstraZeneca as part of a steering committee, and reviewed and agreed in collaboration with UK Breast Cancer Group (UKBCG), Association of Breast Surgery (ABS), and UK Clinical Genetics Group
Interactive gBRCA testing pathway
View an interactive version of the gBRCA testing pathway to support understanding and implementation in clinical practice
Breast Cancer Genetic Testing: Solutions Toolkit
This toolkit is designed to support the implementation of gBRCA testing in your treatment pathway. It signposts to resources and tools available in the NHS which were highlighted during an AstraZeneca steering committee
GB-66801 | May 2025
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
